ASPIrin in Reducing Events in Dialysis ( ASPIRED )

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: CKD (Chronic Kidney Disease) Stage 5D

In brief

People with kidney failure requiring dialysis have a much higher risk of developing cardiovascular (CV) disease compared with the general population. A cardiac cause accounts for 58% of all deaths in patients with end stage kidney disease (ESKD). At the same time, this population has increased risks of clotting as well as bleeding episodes. While aspirin is known to reduce cardiovascular complications in the general population, evidence to support the use of aspirin in people with ESKD receiving dialysis therapy is currently lacking. The ASPIrin to Reduce Event in Dialysis (ASPIRED) trial will test whether aspirin use in dialysis patients safely improves outcomes compared with no aspirin use.

Key facts

Study ID
NCT04381143
Run by
Guangdong Provincial People's Hospital
People needed
9000
Starts
2020-07-30
Expected to finish
2026-12-01
Last updated by the study team
2025-11-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.